Neoadjuvant chemoradiotherapy of stage III non-small-cell lung cancer.

Abstract

Twenty to 30% of patients with non-small-cell lung cancer (NSCLC) in stage III are not resectable primarily with 5-year survival less than 10%. Since the majority of patients die from metastases, efforts have been made in the past to improve prognosis by application of neoadjuvant chemoradiotherapy regimens followed by subsequent resection. In a phase II study performed between 1993 and 1998, 93 patients in stage III (IIIA, 16%; IIIB, 84%) received an induction chemotherapy consisting of two cycles cisplatin (100 mg/m2) and vindesine (3 mg/m2) with subsequent sequential radiotherapy of 36 Gy. Sixty-five patients demonstrated partial or complete remission. Sixty underwent surgery; in 49 of them complete resection was possible. Five-year survival in the whole group was 24%, and that in the surgical cohort 39%. Six patients had no residual tumor. Postoperative N0 status was associated with a 5-year survival of 75%, and stage N1-3 with 13%. Thirty-day mortality was 7% postoperatively. Neoadjuvant chemoradiotherapy can significantly improve long-term survival in stage III NSCLC with an acceptable therapy-induced mortality.

• Authors: G Friedel, D Hruska, W Budach, M Wolf, T Kyriss, M Hürtgen, H P Eulenbruch, R Dierkesmann, H Toomes
• Journal: Lung cancer (Amsterdam, Netherlands) (Lung Cancer) Vol. 30 Issue 3 Pg. 175-85 (Dec 2000) ISSN: 0169-5002 [Print] Ireland
• PMID: 11137202 (Publication Type: Clinical Trial, Clinical Trial, Phase II, Journal Article)

Chemical References

• Cisplatin
• Vindesine

Topics

• Adult
• Aged
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Carcinoma, Non-Small-Cell Lung (drug therapy, radiotherapy, surgery)
• Cisplatin (administration & dosage)
• Female
• Humans
• Lung Neoplasms (drug therapy, radiotherapy, surgery)
• Male
• Middle Aged
• Neoadjuvant Therapy
• Neoplasm Invasiveness
• Prospective Studies
• Survival Analysis
• Treatment Outcome
• Vindesine (administration & dosage)